UBS/CALL/MODERNA/150.001/0.1/20.09.24 | Real-time Bid/Ask 06:05:59 2024-06-05 EDT | ||
| 1.35 CHF / 1.38 CHF | +4.20% |
|
| Current month | -14.38% | ||
| 1 month | +107.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 1.31 | -16.56% |
| 24-06-03 | 1.57 | +2.61% |
| 24-05-31 | 1.53 | +14.18% |
| 24-05-30 | 1.34 | -2.19% |
| 24-05-29 | 1.37 | -26.34% |
Delayed Quote Swiss Exchange
Last update June 04, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| QMRNMU | |
| ISIN | CH1312549780 |
| Date issued | 2024-01-08 |
| Strike | 150 $ |
| Maturity | 2024-09-20 (108 Days) |
| Parity | 10 : 1 |
| Emission price | 0.86 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.73 CHF |
|---|---|
| Lowest since issue | 0.18 CHF |
| Spread | 0.03 CHF |
| Spread % | 2.17% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Warrants
- QMRNMU Warrant
